The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.
 
Tina Cascone
No Relationships to Disclose
 
Vivek Subbiah
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
 
Kenneth R. Hess
Travel, Accommodations, Expenses - Angiochem
 
Sarah Nelson
No Relationships to Disclose
 
Monique B. Nilsson
No Relationships to Disclose
 
Ishwaria Mohan Subbiah
Research Funding - Bayer (I); GlaxoSmithKline (I); Novartis (I); Roche/Genentech (I)
 
Siraj Mahamed Ali
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
David Paul Carbone
Employment - James Cancer Center
Consulting or Advisory Role - Bayer; Biothera; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Merck; Novartis; Peregrine Pharmaceuticals; Pfizer; Synta; Synta
Research Funding - Bristol-Myers Squibb
 
Ravi Salgia
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Bayer; Celgene; Genentech/Roche; Novartis
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Celgene (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Genetic predictor of chemotherapy sensitivity (Inst)
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem
 
Robert Charles Doebele
Honoraria - AstraZeneca; Clovis Oncology; Loxo; OxOnc; Pfizer
Consulting or Advisory Role - Array BioPharma; Lilly; Loxo; OxOnc; Pfizer; Pfizer
Research Funding - Abbott Molecular; Loxo; Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Licensing Fees for Biologic Material from Ariad (Inst); Licensing Fees for Biologic Material from Blueprint Medicines (Inst); Licensing Fees for Biologic Material from Chugai (Inst); Licensing Fees for Biologic Materials from GVKbio; Licensing Fees for Biologic Materials from Loxo Oncology (Inst); Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495
Travel, Accommodations, Expenses - Ignyta
 
John Heymach
No Relationships to Disclose